Fintech PR
Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight
The overall chronic rhinosinusitis with nasal polyps market is expected to grow due to the increase in the diagnosed prevalent population of CRSwNP across the globe and thus the surge in demand for treatment. The expected launch of emerging therapies will further boost the CRSwNP treatment market in the forecasted period (2023–2032).
LAS VEGAS, Dec. 7, 2023 /PRNewswire/ — DelveInsight’s Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Chronic Rhinosinusitis with Nasal Polyps Market Report
- As per DelveInsight analysis, the total CRSwNP market size in the 7MM was approximately USD 1.8 million in 2022 and is projected to increase during the forecast period (2023–2032).
- As per DelveInsight estimates, there were 4.3 million diagnosed prevalent cases of CRSwNP estimated to have occurred in the 7MM in 2022.
- Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
- The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
Discover which therapies are expected to grab the major chronic rhinosinusitis with nasal polyps market share @ Chronic Rhinosinusitis with Nasal Polyps Market Report
Chronic Rhinosinusitis with Nasal Polyps Overview
Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks. Patients suffering from CRS can develop CRS with nasal polyposis (CRSwNP) and CRS without nasal polyposis (CRSsNP). CRSwNP is thus a subset of CRS, with roughly one-fourth of CRS patients developing the disease. Chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, susceptibility to NSAIDs like ibuprofen and aspirin, and Churg-Strauss syndrome are all risk factors for CRSwNP. Chronic nasal congestion, running nose, postnasal drip, decreased sense of smell and taste, trouble breathing, pressure in the face or forehead area, snoring, sleep apnea, anterior or posterior rhinorrhea, and other symptoms may occur. An ENT expert or another physician examines the nasal passages with a special illuminated equipment known as a nasoscope to make the initial diagnosis of CRSwNP. Nasal endoscopy and radiological imaging are the most commonly used procedures for validating the location, size, and severity of polyps.
Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation
The diagnosed prevalent cases of CRSwNP were further divided into Gender-specific cases. The Gender-specific diagnosed prevalent cases of CRSwNP are categorized into males and females with 1.2 million and 986K cases respectively in the US in 2022, which is expected to further increase in 2032.
The chronic rhinosinusitis with nasal polyps market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Prevalent Cases of Chronic Rhinosinusitis
- Diagnosed Prevalent Cases of Chronic Rhinosinusitis
- Diagnosed Prevalent Cases of CRSwNP
- Gender-specific Diagnosed Prevalent Cases of CRSwNP
Chronic Rhinosinusitis with Nasal Polyps Treatment Market
Depending on the specific instance, the typical treatment for CRSwNP includes a combination of pharmacological and surgical treatments. Patients are generally treated medically in primary care settings before considering surgical options. Treatment attempts to eradicate or greatly reduce the size of the CRSwNP, resulting in nasal obstruction reduction, sinus drainage improvement, and olfaction and taste restoration. Any associated rhinitis symptoms may also necessitate treatment. Recurrences are prevalent with both therapies, especially in asthma sufferers, who are twice as likely as nonasthmatics to develop recurrence.
CRSwNP is currently treated with corticosteroids (both intranasal and systemic), as well as antihistamines, antibiotics, and NSAIDs, which are provided based on the patient’s needs. Endoscopic surgery is indicated to remove polyps and fix problems with your sinuses that make them prone to inflammation and the growth of polyps when medication treatment does not shrink or eliminate nasal polyposis. In addition to biologics, corticosteroid nasal spray is indicated after surgery to avoid the recurrence of nasal polyposis. XHANCE (fluticasone propionate), SINUVA (mometasone furoate) Sinus Implant, PROPEL (mometasone furoate), DUPIXENT (dupilumab), XOLAIR (omalizumab), and NUCALA (mepolizumab) have all been authorized by the US FDA for the treatment of CRSwNP.
Intranasal glucocorticoids (budesonide, fluticasone, and mometasone) may improve rhinorrhea, reduce polyp growth, and partially or completely restore the sense of smell. According to experts, physicians tend to under-administer intranasal glucocorticoids and prescribe them at levels that are ineffective. Patients also tend to take these products seldom when they are prescribed.
To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management
Chronic Rhinosinusitis with Nasal Polyps Pipeline Therapies and Key Companies
- FASENRA (benralizumab): AstraZeneca
- TEZSPIRE (tezepelumab): AstraZeneca/Amgen
- Depemokimab/GSK3511294: GlaxoSmithKline
- CM310: Keymed Biosciences
- NURTEC (rimegepant): Biohaven Pharmaceuticals
Learn more about the FDA-approved drugs for chronic rhinosinusitis with nasal polyps @ Drugs for Chronic Rhinosinusitis with Nasal Polyps Treatment
Chronic Rhinosinusitis with Nasal Polyps Market Dynamics
The dynamics of the chronic rhinosinusitis with nasal polyps are expected to change in the coming years. The disease’s increasing prevalence is likely to result in an increase in treatment choices, and as a result, the market may see an increase in the coming years. The recent entrance of NUCALA and XOLAIR into the CRSwNP market has provided additional biologic choices to choose from. Because almost half of CRSwNP patients do not know the reason of their symptoms, proactive initiatives to target this patient demographic could boost the entire CRSwNP market. There are prospects for cost-effective treatment solutions for people with severe recurrent CRSwNP.
Furthermore, many potential therapies are being investigated for the treatment of CRSwNP, and it is safe to predict that the treatment space will significantly impact the CRSwNP market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the CRSwNP market in the 7MM.
However several factors may impede the growth of the CRSwNP market. Current medicines, such as corticosteroids, are not differentiated based on the severity of the condition, but rather are used in all patients. A significant proportion of CRSwNP patients remain undiagnosed, which may impede CRSwNP market expansion. Another major cause of bad present patient care is a lack of disease knowledge among doctors, which may impede CRSwNP market expansion. In addition, the availability of less expensive off-label medications on the CRSwNP market, might provide a hurdle to new therapies.
Moreover, CRSwNP treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the CRSwNP market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the CRSwNP market growth.
|
Report Metrics |
Details |
|
Study Period |
2019–2032 |
|
Coverage |
7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. |
|
Chronic Rhinosinusitis with Nasal Polyps Market CAGR |
10.03 % |
|
Chronic Rhinosinusitis with Nasal Polyps Market Size in 2022 |
USD 1.8 Billion |
|
Key Chronic Rhinosinusitis with Nasal Polyps Companies |
AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others |
|
Key Pipeline Chronic Rhinosinusitis with Nasal Polyps Therapies |
FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others |
Scope of the Chronic Rhinosinusitis with Nasal Polyps Market Report
- Therapeutic Assessment: Chronic Rhinosinusitis with Nasal Polyps current marketed and emerging therapies
- Chronic Rhinosinusitis with Nasal Polyps Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Rhinosinusitis with Nasal Polyps Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Chronic Rhinosinusitis with Nasal Polyps Market Access and Reimbursement
Discover more about chronic rhinosinusitis with nasal polyps drugs in development @ Chronic Rhinosinusitis with Nasal Polyps Clinical Trials
Table of Contents
|
1. |
Chronic Rhinosinusitis with Nasal Polyps Key Insights |
|
2. |
Chronic Rhinosinusitis with Nasal Polyps Report Introduction |
|
3. |
Chronic Rhinosinusitis with Nasal Polyps Overview at a Glance |
|
4. |
Chronic Rhinosinusitis with Nasal Polyps Executive Summary |
|
5 |
Chronic Rhinosinusitis with Nasal Polyps Key Events |
|
6 |
Epidemiology and Market Forecast Methodology |
|
6. |
Disease Background and Overview |
|
7. |
Chronic Rhinosinusitis with Nasal Polyps Treatment and Management |
|
8. |
Chronic Rhinosinusitis with Nasal Polyps Guidelines |
|
9. |
Chronic Rhinosinusitis with Nasal Polyps Epidemiology and Patient Population |
|
10. |
Patient Journey |
|
11. |
Key Endpoints in Chronic Rhinosinusitis with Nasal Polyps |
|
12. |
Chronic Rhinosinusitis with Nasal Polyps Marketed Drugs |
|
13. |
Chronic Rhinosinusitis with Nasal Polyps Emerging Drugs |
|
14. |
7MM Chronic Rhinosinusitis with Nasal Polyps Market Analysis |
|
15. |
Market Access and Reimbursement |
|
16. |
KOL Views |
|
17. |
Unmet Needs |
|
18. |
SWOT Analysis |
|
19. |
Appendix |
|
20. |
DelveInsight Capabilities |
|
21. |
Disclaimer |
|
22. |
About DelveInsight |
Related Reports
Chronic Rhinosinusitis with Nasal Polyps Epidemiology Forecast
Chronic Rhinosinusitis with Nasal Polyps Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and chronic rhinosinusitis with nasal polyps epidemiology trends.
Chronic Rhinosinusitis with Nasal Polyps Pipeline
Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic rhinosinusitis with nasal polyps companies, including Keymed Biosciences, Connect Biopharma, AstraZeneca, Amgen, Pfizer, Trellis Bioscience LLC, GlaxoSmithKline, Gossamer Bio Inc., Biohaven Pharmaceuticals, Inc., Insmed Incorporated, Lyra Therapeutics, among others.
Chronic Rhinosinusitis without Nasal Polyps Market
Chronic Rhinosinusitis without Nasal Polyps Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic rhinosinusitis without nasal polyps companies including AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, among others.
Chronic Rhinosinusitis without Nasal Polyps Epidemiology
Chronic Rhinosinusitis with Nasal Polyps Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and chronic rhinosinusitis without nasal polyps epidemiology trends.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo – https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:
Fintech PR
President Emmerson Mnangagwa met this week with Zambia’s former Vice President and Special Envoy Enoch Kavindele to discuss SADC’s candidate for the AfDB
President Mnangagwa, who is SADC Chairperson, reaffirmed his own country’s and SADC’s enthusiastic support for Zambian candidate Sam Maimbo
LUSAKA, Zambia, Dec. 20, 2024 /PRNewswire/ — Special Envoy Kavindele released the following statement following the meeting:
“I am elated to witness the growing success and momentum of Sam Maimbo’s candidacy to become the next President of the African Development Bank. I am filled with gratitude to our friends across both SADC and COMESA for their continued support and good wishes.
Sam has garnered such wide consensus due to his being uniquely qualified to deliver the transformative change and empowerment our continent needs. Sam’s 30 years in development work is defined by driving outcomes, improving processes, and investing in people. The AfDB needs a hands-on leader who is laser focused on delivering results and who is unafraid of making tough decisions in order to best serve our continent. Sam is that leader. Sam has the track record and experience to drastically enhance the pace, scale, and impact of the Bank’s work in service of the people and governments of Africa.
Our region has a proud history of supporting fellow Southern Africans. For example, we all recall Lusaka’s role in hosting the African National Congress’ headquarters during the dark days of Apartheid oppression.
It therefore gives me no pleasure to observe my South African brothers, who have themselves leant on Zambia’s steadfast friendship over many decades, fail to rally behind both SADC and COMESA’s chosen candidate for the AfDB. Africa’s urgent economic development challenges demand transformational leadership at the AfDB, it is all of our responsibility to put forward the best candidate for the job. This is not the time or place for a government to act with narrow self-interest, we all must act in the continent’s and AfDB’s best interest.
I thank Sam Maimbo for his lifelong service to our entire continent, and I am eager to witness his enormous impact as President of the AfDB.”
LONDON, Dec. 20, 2024 /PRNewswire/ — Heimdal Security shares a practical holiday cybersecurity checklist, offering expert insights to help businesses safeguard against cyber threats this festive season.
With reduced staffing, remote work setups, and a surge in online shopping creating heightened vulnerabilities, this guide offers actionable tips to enhance business security.
Going beyond basic advice, the checklist also highlights the most common holiday scams and features videos showcasing real-life examples of Christmas-themed cyber scams and effective prevention strategies.
Key Tips to Protect Businesses This Holiday Season:
- Strengthen endpoints: Ensure devices are updated with antivirus and endpoint protection software; consider Endpoint Detection and Response (EDR) and application whitelisting.
- Prepare for phishing spikes: Train staff to identify suspicious emails, enforce robust email filters, and establish protocols for reporting unusual activity.
- Secure remote access: Mandate VPN usage, monitor unusual logins, and deactivate inactive accounts temporarily.
- Segment and shield networks: Isolate sensitive areas, deploy DNS security and advanced firewalls, and maintain full visibility over network traffic.
- Apply timely patches: Regularly update all systems and test patches in a controlled environment to minimize disruptions.
- Mitigate supply chain risks: Assess vendors thoroughly and limit their access to essential systems.
- Have a response plan ready: Tailor incident protocols for the holidays, create an on-call rotation for the IT team, and enable rapid action against suspicious activity.
“ Cybercriminals thrive on holiday distractions, but with proactive measures like phishing training, secure endpoints, and network segmentation, businesses can stay ahead of potential threats,” said Alex Panait, System Administrator at Heimdal Security.
Common Holiday Scams That Businesses Should Watch For:
Cybercriminals often tailor their tactics to exploit the festive season. The most common scams include:
- Spear phishing: Emails disguised as holiday bonuses or event invitations that steal credentials or spread malware.
- Malicious holiday E-Cards: Festive greetings that contain links deploying ransomware or spyware.
- Fake E-Commerce sites: Fraudulent websites offering discounts to steal payment information.
- Insider threats: Distracted or disgruntled employees mishandling or exploiting sensitive data.
- Corporate travel scams: Fake booking platforms targeting business travelers.
- Business email compromise (BEC): Fraudulent requests for urgent wire transfers during year-end financial rushes.
For more, read the full article here or watch the video on YouTube to see how these threats unfold and learn actionable prevention strategies.
About Heimdal:
Established in Copenhagen in 2014, Heimdal® empowers CISOs, security teams, and IT administrators to improve their security operations, reduce alert fatigue, and implement proactive measures through a unified command and control platform.
Heimdal’s award-winning cybersecurity solutions span the entire IT estate, addressing challenges from endpoint to network levels, including vulnerability management, privileged access, Zero Trust implementation, and ransomware prevention.
For further press information:
Madalina Popovici
Media Relations Manager
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/stay-cyber-safe-this-holiday-season-heimdals-checklist-for-business-security-302337465.html
Fintech PR
According to Tickmill survey, 3 in 10 Britons in economic difficulty: Purchasing power down 41% since 2004
The people who have the most problems are women (30%) and are between 35 and 49 years old (39%)
ROME, Dec. 20, 2024 /PRNewswire/ — The purchasing power in the UK has dropped by 41% over the last 20 years. Today, £100,000 left in a bank account since 2004 without being invested would now be worth £59,021.
This figure is one of the findings from a study conducted by Tickmill, an international online trading broker that compared the economic situation in the UK and the European Union through the infographic “Purchasing Power and Cost of Living: UK vs EU”.
The analysis reveals a slight decline of 0.4% in the UK’s purchasing power, which currently stands at £41,573. In contrast, the European Union has seen a modest rise of 0.1%, reaching £40,874.
Why is purchasing power declining in the UK? One key factor is the cost of living. If the UK were still part of the European Union, it would rank as the fifth most expensive country, behind Ireland, Luxembourg, Denmark, and the Netherlands.
Unsurprisingly, 3 in 10 Britons are struggling with the cost of living. Women (3 in 10, compared to 25% of men), those aged between 35 and 49 (4 in 10), households earning less than £15,000 (6 in 10), and single parents (1 in 2) are among the most affected groups.
Among UK nations, Northern Ireland is the hardest hit, with 34% of its population facing financial difficulties, followed by Wales (31%), England (28%), and Scotland (22%). In England, the North East has the highest percentage of people struggling, with 4 in 10 residents affected. Even in London, the high costs impact 1 in 4 adults.
In response to these challenges, Britons are making significant adjustments:
- 53% have cut back or delayed spending on smaller items like eating out, entertainment, subscriptions, clothing, toys, books, etc.;
- 52% have reduced household energy consumption;
- 48% have decreased their grocery spending;
- 41% have scaled back or postponed major expenditures, such as holidays, cars, and weddings;
- 26% are working longer hours, taking on overtime, or pursuing additional jobs to earn extra income.
The British also made changes on the financial side. One in four adults has been forced to dip into their savings or investments to cover daily expenses. Moreover, 44% have stopped saving or investing entirely or have reduced their savings and investments—a 4% increase compared to 2023.
The lack of investment is another critical factor contributing to the decline in purchasing power. It is estimated that 13 million UK residents hold £430 billion in cash deposits but do not invest. The reasons? Seventy-four percent say they cannot compare investment products effectively, and 43% are afraid of losing their money.
A lack of knowledge and fear are preventing many savers from taking advantage of an important opportunity: preserving or increasing their purchasing power in the long term.
Photo: https://mma.prnewswire.com/media/2586123/Tickmill.jpg
Logo: https://mma.prnewswire.com/media/2586129/Tickmill_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/according-to-tickmill-survey-3-in-10-britons-in-economic-difficulty-purchasing-power-down-41-since-2004-302337354.html
-
Fintech5 days agoFintech Pulse: Your Daily Industry Brief (Synapse, Shenzhen Institute, Visa, AutomatIQ, MeridianLink)
-
Fintech4 days agoFintech Pulse: Your Daily Industry Brief (Revolut, Bestow, Advyzon, Tyme Group, Nubank)
-
Fintech2 days agoFintech Pulse: Your Daily Industry Brief (Chime, ZBD, MiCA)
-
Fintech4 days agoAsian Financial Forum returns as region’s first major international financial assembly in 2025
-
Fintech5 days agoNASDAQ-Listed LYTUS Appoints Visionary Leader Sai Guna Ranjan Puranam as COO (Lytus Healthcare) and Group CTO (Lytus Technologies) to Revolutionize Healthcare and Technology
-
Fintech5 days agoDhaka Court Dismisses Allegations Against Nagad Founder Tanvir A Mishuk
-
Fintech PR3 days agoGan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)
-
Fintech PR5 days agoFrost & Sullivan Recognizes AllianceOne and Central Florida Expressway Authority with 2024 Customer Value Leadership Award